The FDA’s Center for Drug Evaluation and Research granted approval for ANDA071510, submitted by Natco Pharma USA, for an oral capsule containing 7.5 mg of clorazepate dipotassium. The product, identified as product number 001, is currently listed with a marketing status of discontinued and is not designated as a reference drug.
The original ANDA submission (submission number 1) received approval on October 19, 1987. Subsequent supplemental submissions (numbers 2, 3, and 5) were approved for labeling changes on December 16, 2016, and August 21, 2025 (two approvals), respectively.
Actualizaciones regulatorias17 sept 2026•3 min de lectura
FDA Approves ANDA071510 for Clorazepate Dipotassium Oral Capsule
The FDA has approved ANDA071510 for a 7.5 mg oral capsule of clorazepate dipotassium, with the product now listed as discontinued and several labeling supplements approved.
Recopilado por el equipo de Pharmacountry · Fuente: FDA.gov
Temas:
Calificaciones
(0)
(0)
(0)
(0)
(0)
Deja tu valoración